BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October

BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer

Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.

BioLineRx (BLRX) Q1 2026 Earnings Transcript

BioLineRx reported Q1 2026 results with a net loss of $2.6 million versus net income of $5.1 million in Q1 2025. The company initiated a Phase I/IIa trial for GLIX1 in glioblastoma with first patient dosed at NYU Langone Health, supported by preclinical data showing dose-dependent tumor growth inhibition. APHEXDA royalty revenues increased to $0.5 million from $0.3 million as Ayrmid's sales grew to $2.5 million. The company ended the quarter with $17.4 million in cash, sufficient to fund operations into H1 2027.